ストックスクリーナーアプリを入手
207.57
1.09%
-2.2991
Revolution Medicines Inc (RVMD) 最新ニュース
Revolution Medicines nears lease for 700,000-square-foot Redwood City campus - The Business Journals
Revolution Medicines (NASDAQ: RVMD) trust plans 3,000-share Rule 144 sale - Stock Titan
Revolution Medicines (NASDAQ: RVMD) director plans August stock sale after June $1.6M trade - Stock Titan
Revolution Medicines (NASDAQ: RVMD) holder eyes $16M stock sale - Stock Titan
RVMD Maintained by Bernstein -- Price Target Raised to $179 - GuruFocus
REVOLUTION MEDICINES, INC. : BERNSTEIN RAISES TARGET PRICE TO $179 FROM $151 - Bitget
Price to sales forward of Revolution Medicines, Inc. – NASDAQ:RVMDW - TradingView
Enterprise value to revenue forward of Revolution Medicines, Inc. – NASDAQ:RVMDW - TradingView
Why Revolution Medicines May Be Big Pharma’s Next Takeover Target - AOL.com
Price to book forward of Revolution Medicines, Inc. – NASDAQ:RVMDW - TradingView
Revolution (RVMDW) Price and Levels: Advances 4.09% to $12.59 in Latest Trading; Technical Focus: the $11.96 to $13.22 Range Remains in Focus in the Available RecordBollinger Walk - Vinanet
Why Revolution Medicines (RVMD) Stock Is Up Today - Quiver Quantitative
Revolution Medicines stock hits all-time high at 208.77 USD - Investing.com
Revolution Medicines stock hits all-time high at 208.77 USD By Investing.com - Investing.com Australia
Corcept, Revolution Medicines lead ten large-cap healthcare stocks surging in 2026 (XLV:NYSEARCA) - Seeking Alpha
Revolution Medicines, Inc. (RVMD) Stock Analysis: Exploring Growth Potential with RAS-Targeted Therapies - DirectorsTalk Interviews
State of Wyoming Buys Shares of 9,446 Revolution Medicines, Inc. $RVMD - MarketBeat
S&CO Inc. Invests $6.40 Million in Revolution Medicines, Inc. $RVMD - MarketBeat
Revolution Medicines (MEX:RVMD) Shiller PE Ratio : (As of Aug. 16, 2026) - GuruFocus
Revolution Medicines Inc Stock Baskets - GuruFocus
Is BeOne Medicines AG (ONC) Deal With Revolution Medicines (RVMD) a Win-Win for Both Companies? - Yahoo Finance
Baker Bros. Advisors (RVMD) discloses 11.4M-share position in Revolution Medicines - Stock Titan
Top Revolution Medicines (RVMDW) Competitors 2026 - MarketBeat
Farallon funds disclose 13.6M-share RVMD stake in Schedule 13G/A filing - Stock Titan
Revolution Medicines (RVMD): Janus Henderson discloses 5.1% beneficial stake - Stock Titan
ERAS Stock Slumps Nearly 40% After-Hours: Fine Print In 'Positive' Cancer Trial Reveals Treatment-Related Death - Stocktwits
Revolution Medicines (RVMD) Q2 2026 Earnings Call Transcript - AOL.com
(RVMD) Volatility Zones as Tactical Triggers - Stock Traders Daily
Revolution and BeOne Meds enter research pact - thepharmaletter.com
Revolution Medicines hits $44B market cap with breakthrough RAS cancer drugs, attracting big pharma interest. - Pluang
Propanc Biopharma Highlights Differentiated Proenzyme Therapy PRP as a Potential Therapy of Choice Against RAS-Driven Cancers - The Manila Times
Revolution Medicines (RVMD) Stock Looks Strong On Returns But Expensive On Value - simplywall.st
Tema ETFs LLC Sells 26,443 Shares of Revolution Medicines, Inc. $RVMD - MarketBeat
Handelsbanken Fonder AB Raises Stock Position in Revolution Medicines, Inc. $RVMD - MarketBeat
Revolution Medicines (RVMD) Stock Looks Rich On Fresh RAS Drug Demand - Yahoo Finance
Revolution Medicines (RVMD) Is Up 6.2% After BeOne-Funded Phase 3 RAS(ON) DealHas The Bull Case Changed? - Yahoo Finance
Revolution Medicines (RVMD) Looks Fairly Valued As BeOne Deal Expands Its Asia Reach - Yahoo Finance
Can Revolution Medicines (RVMD) Turn A New Ally Into Global Reach? - Yahoo Finance
BeOne and Revolution Medicines partner for oncology therapies - Pharmaceutical Business review -
BeOne Medicines Enters Collaboration with Revolution Medicines for Oncology Therapies - Pharmaceutical Executive
REVOLUTION MEDICINES, INC. : TRUIST SECURITIES RAISES TARGET PRICE TO $231 FROM $210 - Bitget
Revolution Medicines (NASDAQ:RVMD) Sets New 12-Month HighShould You Buy? - MarketBeat
Bank of America Corp DE Cuts Holdings in Revolution Medicines, Inc. $RVMD - MarketBeat
‘Pharma Bro’ Martin Shkreli Defends Revolution Medicines’ Pancreatic Cancer Study Data: ‘Progress Compounds’ - Stocktwits
Revolution Medicines (RVMD) BeOne Deal Puts Its Valuation Back In Focus - simplywall.st
BeOne and Revolution Medicines partner on RAS(ON) inhibitor combinations in Asia - AllSci
RevMed, BeOne make clinical trial, Asia deal; MoonLake reports Phase 3 win - Endpoints News
Revolution Medicines stock rating reiterated at Buy by TD Cowen - Investing.com South Africa
BeOne Medicines and Revolution Medicines Partner on RAS(ON) Cancer Therapies - Oncodaily
BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration - BioSpace
Revolution Medicines, BeOne Medicines form collaboration on RAS cancer drug combinations - Bitget
BeOne Medicines And Revolution Medicines Announce Clinical Development And Regional Commercialization Collaboration - TradingView
Revolution Medicines, Inc. (RVMD) Stock Analysis: A Biotech Powerhouse with a Bold Vision for Cancer Treatment - DirectorsTalk Interviews
REVOLUTION MEDICINES, INC. : JP MORGAN RAISES TARGET PRICE TO $227 FROM $205 - Bitget
Why Revolution Medicines (RVMD) Is Up 9.4% After Mounting Losses And Surging Daraxonrasib Demand – And What's Next - webull.com
Assenagon Asset Management S.A. Buys Shares of 200,486 Revolution Medicines, Inc. $RVMD - MarketBeat
LifeSci Capital Maintains Revolution Medicines(RVMD.US) With Buy Rating, Maintains Target Price $291 - moomoo.com
0.73%
4.90%
大文字化:
|
ボリューム (24 時間):